These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37872057)

  • 41. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells.
    Shivshankar P; Li YD; Mueller-Ortiz SL; Wetsel RA
    FASEB J; 2020 Jun; 34(6):7540-7560. PubMed ID: 32301538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Corrigendum to "Different roles of bortezomib and ONX 0914 in acute kidney injury" [Int. Immunopharmacol. 82 (2020) 106259].
    Zhang XZ; Han F; Ding CG; Dou M; Wang YX; Xue WJ; Ding XM; Zheng J; Xu CX; Tian PX
    Int Immunopharmacol; 2024 Jan; 126():111189. PubMed ID: 38012900
    [No Abstract]   [Full Text] [Related]  

  • 43. Corrigendum to "Leukotriene D4 induces cellular senescence in osteoblasts" [Int. Immunopharmacol. 58 (2018)154-159].
    Wei J; Chen S; Guo W; Feng B; Yang S; Huang C; Chu J
    Int Immunopharmacol; 2024 Mar; 129():111673. PubMed ID: 38365537
    [No Abstract]   [Full Text] [Related]  

  • 44. Corrigendum to "Wedelolactone induces apoptosis and pyroptosis in retinoblastoma through promoting ROS generation" [Int. Immunopharmacol. 111 (2022) 108855].
    Jiang H; Niu C; Guo Y; Liu Z; Jiang Y
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111146. PubMed ID: 37926666
    [No Abstract]   [Full Text] [Related]  

  • 45. Corrigendum to "Effect of chlorogenic acid on mast cell-dependent anaphylactic reaction" [Int. Immunopharmacol. 10 (2010) 1135-1141].
    Qin HD; Shi YQ; Liu ZH; Li ZG; Wang HS; Wang H; Liu ZP
    Int Immunopharmacol; 2019 Nov; 76():105863. PubMed ID: 31473097
    [No Abstract]   [Full Text] [Related]  

  • 46. Corrigendum to "Immune-enhancing effects of polysaccharides extracted from Lilium lancifolium Thunb" [Int. Immunopharmacol. 52 (2017) 119-126].
    Pan G; Xie Z; Huang S; Tai Y; Cai Q; Jiang W; Sun J; Yuan Y
    Int Immunopharmacol; 2018 May; 58():186. PubMed ID: 29599101
    [No Abstract]   [Full Text] [Related]  

  • 47. Corrigendum to "Circulating midkine in children with Henoch-Schönlein purpura: Clinical implications" [Int. Immunopharmacol. (2016) 246-250].
    Su Z; Lv X; Liu Y; Zhang J; Guan J; Gai Z
    Int Immunopharmacol; 2016 Dec; 41():145. PubMed ID: 27612398
    [No Abstract]   [Full Text] [Related]  

  • 48. Corrigendum to "Neuroprotective effect of Vesatolimod in an experimental autoimmune encephalomyelitis mice model" [Int. Immunopharmacol. 116 (2023) 109717].
    Jiang X; Song Y; Fang J; Yang X; Mu S; Zhang J
    Int Immunopharmacol; 2024 Feb; 128():111448. PubMed ID: 38191277
    [No Abstract]   [Full Text] [Related]  

  • 49. Corrigendum to "MEGF6 prevents sepsis-induced acute lung injury in mice" [Int. Immunopharmacol. 123 (2023) 110727].
    Liang H; Liu G; Zeng W; Fan Q; Nie Z; Hu H; Zhang R; Xie S
    Int Immunopharmacol; 2024 May; 133():111787. PubMed ID: 38641473
    [No Abstract]   [Full Text] [Related]  

  • 50. Corrigendum to "Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine" [Int. Immunopharmacol. 131 (2024) 111817].
    Yu X; Min H; Yao S; Yao G; Zhang D; Zhang B; Chen M; Liu F; Cui L; Zheng L; Cao Y
    Int Immunopharmacol; 2024 Aug; 137():112260. PubMed ID: 38926073
    [No Abstract]   [Full Text] [Related]  

  • 51. Corrigendum to "Modulating endoplasmic reticulum stress attenuates mast cell degranulation" [Int. Immunopharmacol. 126 (2024) 111336].
    Fan J; Ma L; Xie B; Qiu S; Song S; Tang Z; Wu Y; Huangfu H; Feng Y; Luo X; Yang P
    Int Immunopharmacol; 2024 Aug; 137():112497. PubMed ID: 38902129
    [No Abstract]   [Full Text] [Related]  

  • 52. Corrigendum to "Emodin attenuates acute lung injury in cecal-ligation and puncture rats" [Int. Immunopharmacol. 85 (2020) 106626].
    Guo R; Li Y; Han M; Liu J; Sun Y
    Int Immunopharmacol; 2023 Sep; 122():110700. PubMed ID: 37507324
    [No Abstract]   [Full Text] [Related]  

  • 53. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217].
    Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y
    Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384
    [No Abstract]   [Full Text] [Related]  

  • 54. Corrigendum to "Thalidomide ameliorate graft chronic rejection in an allogenic kidney transplant model" [Int. Immunopharmacol. 71 (2019) 32-39].
    Zhang Y; Yang Y; Li X; Chen D; Tang G; Men T
    Int Immunopharmacol; 2022 Jun; 107():108584. PubMed ID: 35484056
    [No Abstract]   [Full Text] [Related]  

  • 55. Corrigendum to "Paeonol derivative-6 attenuates inflammation by activating ZEB2 in acute liver injury" [Int. Immunopharmacol. 91 (2021) 107235].
    Yang J; Xu L; Wu M; Fang H; Lu Y; Shi C; Wang Y; Li Z; Zhang L; Zhang L
    Int Immunopharmacol; 2021 May; 94():107410. PubMed ID: 33578262
    [No Abstract]   [Full Text] [Related]  

  • 56. Corrigendum to "Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice" [Int. Immunopharmacol. 59 (2018) 269-275].
    Luo S; Deng X; Liu Q; Pan Z; Zhao Z; Zhou L; Luo X
    Int Immunopharmacol; 2018 Sep; 62():337. PubMed ID: 29983242
    [No Abstract]   [Full Text] [Related]  

  • 57. Corrigendum to "Neutrophil elastase in dexmedetomidine alleviating sepsis-related renal injury in rats" [Int. Immunopharmacol. 122 (2023) 110441].
    Chen L; Li M; Lin Y; Li Y; Liang M; Zeng K
    Int Immunopharmacol; 2024 Feb; 128():111577. PubMed ID: 38281885
    [No Abstract]   [Full Text] [Related]  

  • 58. Complement Regulation in Human Tenocytes under the Influence of Anaphylatoxin C5a.
    Silawal S; Kohl B; Shi J; Schulze-Tanzil G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Corrigendum to "Biomimetic amphiphilic FAAP NPs nanoparticles: Synthesis, characterization and antivirus activity" [Int. Immunopharmacol. 101(Part A) (2021) 108047].
    Li X; Zhang Z; Ma X; Guo Z; Ban X; Tian Z; Zhao L; Liu Q; He Q
    Int Immunopharmacol; 2023 Sep; 122():110735. PubMed ID: 37544813
    [No Abstract]   [Full Text] [Related]  

  • 60. Corrigendum to "Ameliorative effects of 3,4-oxo-isopropylidene-shikimic acid on experimental colitis and their mechanisms in rats" [Int. Immunopharmacol. 15(3) (2013) 524-531].
    Xing J; You C; Dong K; Sun J; You H; Dong Y; Sun J
    Int Immunopharmacol; 2023 Feb; 115():109700. PubMed ID: 36641893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.